ORGANOGENESIS HOLDINGS INC. Accretion Expense
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Accretion Expense of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2020-03-09
- ORGANOGENESIS HOLDINGS INC. accretion expense for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- ORGANOGENESIS HOLDINGS INC. accretion expense for fiscal 2017 was $423.00K.
| Period end | Accretion Expense 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2020-03-09 |
| 2017-12-31 | $423.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |